Immunogenecity of hepatitis A vaccine in pediatric patients with inflammatory bowel disease

Background: There are only a few studies on immune response to routine vaccinations in children with inflammatory bowel disease (IBD), despite a strong need for this kind of study. The aim of the study was to evaluate the immunogenicity of an inactivated hepatitis A vaccine (HAV) in IBD pediatric pa...

Full description

Saved in:

Bibliographic Details
Published in:	Inflammatory bowel diseases 2011-05, Vol.17 (5), p.1117-1124
Main Authors:	Radzikowski, Andrzej, Banaszkiewicz, Aleksandra, Łazowska‐Przeorek, Izabella, Grzybowska‐Chlebowczyk, Urszula, Woś, Halina, Pytrus, Tomasz, Iwańczak, Barbara, Kowalska‐Duplaga, Kinga, Fyderek, Krzysztof, Gawrońska, Agnieszka, Karolewska‐Bochenek, Katarzyna, Kotowska, Maria, Albrecht, Piotr
Format:	Article
Language:	eng
Subjects:	Adolescence Adolescent Age Age Factors Child Children Crohn Disease - immunology Crohn's Disease Enzyme-linked immunosorbent assay Female Hepatitis A Hepatitis A - immunology Hepatitis A - prevention & control Hepatitis A Antibodies - blood Hepatitis A Vaccines - administration & dosage Hepatitis A Vaccines - adverse effects Hepatitis A Vaccines - immunology hepatitis A virus Humans Immune response Immunogenicity inflammatory bowel disease Inflammatory bowel diseases Intestine Male pediatric patients Pediatrics Prospective Studies Seroconversion Side effects Vaccination Vaccines
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Background: There are only a few studies on immune response to routine vaccinations in children with inflammatory bowel disease (IBD), despite a strong need for this kind of study. The aim of the study was to evaluate the immunogenicity of an inactivated hepatitis A vaccine (HAV) in IBD pediatric patients compared with healthy controls. Methods: This was an open, prospective, and controlled study on anti‐HAV‐negative children and adolescents age 2–18 years with IBD. HAV using 720 enzyme‐linked immunosorbent assay (ELISA) units were administered at 0 months and at 6–12 months. Seroconversion and geometric mean titers were measured after each vaccine dose. The evidence of local and systemic adverse effects for 3 days after the first and second dose of vaccine was registered. Results: A total of 134 subjects (66 patients and 68 controls) completed the whole study course consisting of two doses of vaccine and six serum samples. There was no significant difference in the rate of seroconversion between IBD patients and controls when measured after the second dose of vaccine (97% versus 100%, P = 0.2407), but the rate was significantly lower in the IBD group when measured after the first dose (39% versus 64%, P = 0.00001). The mean geometric titers were statistically significantly lower in the IBD group than in the control group at all of the measured timepoints. There were no serious adverse events related to HAV during the study. Conclusions: HAV is both immunogenic and safe in pediatric patients with IBD. (Inflamm Bowel Dis 2010;)
ISSN:	1078-0998 1536-4844 1536-4844